{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:35:07Z","timestamp":1775374507362,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.biopha.2026.118998","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:30:22Z","timestamp":1768923022000},"page":"118998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy"],"prefix":"10.1016","volume":"195","author":[{"given":"Eliza Mathias","family":"Melo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe","family":"Resende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Roque","family":"Ascen\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso Martins","family":"Queiroz-Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-238X","authenticated-orcid":false,"given":"Mario","family":"Amatruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Tomassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Brandolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8390-6614","authenticated-orcid":false,"given":"Andrea","family":"Aramini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-6746","authenticated-orcid":false,"given":"Frederico Marianetti","family":"Soriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Cypriano","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3008","authenticated-orcid":false,"given":"Mauro Martins","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib2","first-page":"51","article-title":"Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis","volume":"6","author":"Fern\u00e1ndez Fabrellas","year":"2018","journal-title":"Med. Sci. (Basel Switz. )"},{"issue":"4","key":"10.1016\/j.biopha.2026.118998_bib3","doi-asserted-by":"crossref","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/crj.13466","article-title":"Idiopathic pulmonary fibrosis: Current and future treatment","volume":"16","author":"Glass","year":"2022","journal-title":"Clin. Respir. J."},{"issue":"3","key":"10.1016\/j.biopha.2026.118998_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/JLB.MA1218-490RR","article-title":"Effect of preventive or therapeutic treatment with angiotensin 1-7 in a model of bleomycin-induced lung fibrosis in mice","volume":"106","author":"Rago","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biopha.2026.118998_bib6","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.biopha.2026.118998_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1183\/09031936.05.00071004","article-title":"Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia","volume":"25","author":"Kondoh","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2026.118998_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/849035","article-title":"Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis","volume":"2011","author":"Tzouvelekis","year":"2011","journal-title":"Pulm. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MOH.0000000000000476","article-title":"The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics","volume":"26","author":"Zhang","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.biopha.2026.118998_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/740987","article-title":"CXCR2 in acute lung injury","volume":"2012","author":"Konrad","year":"2012","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib11","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/s41467-025-60174-w","article-title":"Alveolar epithelial and vascular CXCR2 mediates transcytosis of CXCL1 in inflamed lungs","volume":"16","author":"Thomas","year":"2025","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2026.118998_bib12","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.4049\/jimmunol.0903843","article-title":"CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs","volume":"185","author":"Cai","year":"2010","journal-title":"Journal immunology (Baltimore Md. 1950)"},{"issue":"12","key":"10.1016\/j.biopha.2026.118998_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2018-10-878082","article-title":"CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by Streptococcus pneumoniae serotype 3","volume":"133","author":"Paudel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.118998_bib14","article-title":"CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance","volume":"2022","author":"Komolafe","year":"2022","journal-title":"Int. J. Inflamm."},{"key":"10.1016\/j.biopha.2026.118998_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115175","article-title":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers","volume":"250","author":"Xie","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.118998_bib16","article-title":"Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies","author":"Hussain","year":"2025","journal-title":"NaunynSchmiede 's. Arch. Pharmacol. 10. 1007\/s0021002503970x. Adv. Online Publ."},{"issue":"9","key":"10.1016\/j.biopha.2026.118998_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am. J. Respir. Crit. care Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.118998_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1165\/rcmb.2007-0364OC","article-title":"Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis","volume":"40","author":"Russo","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.biopha.2026.118998_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.566953","article-title":"CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice","volume":"11","author":"Mattos","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib20","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41598-021-83531-3","article-title":"Elevated inflammatory responses and targeted therapeutic intervention in a preclinical mouse model of ataxia-telangiectasia lung disease","volume":"11","author":"Saunders","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/ijms21010227","article-title":"Particulate Matter Increases the Severity of Bleomycin-Induced Pulmonary Fibrosis through KC-Mediated Neutrophil Chemotaxis","volume":"21","author":"Cheng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cea.13275","article-title":"Attenuation of murine allergic airway inflammation with a CXCR1\/CXCR2 chemokine receptor inhibitor","volume":"49","author":"Hosoki","year":"2019","journal-title":"Clinical experimental allergy journal British Society Allergy Clinical Immunology"},{"issue":"11","key":"10.1016\/j.biopha.2026.118998_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70042","article-title":"Opposite effects of systemic and local conditional CD11c+ myeloid cell depletion during bleomycin-induced inflammation and fibrosis in mice","volume":"12","author":"Lopes","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2026.118998_bib24","doi-asserted-by":"crossref","first-page":"L1010","DOI":"10.1152\/ajplung.00233.2017","article-title":"The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2+ and CCR5+ IFN\u03b3-producing \u03b3\u03b4T cells in mice","volume":"314","author":"Russo","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1165\/rcmb.2009-0406OC","article-title":"Therapeutic effects of evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis","volume":"45","author":"Russo","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1189\/jlb.0610346","article-title":"Phosphoinositide 3-kinase \u03b3 plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice","volume":"89","author":"Russo","year":"2011","journal-title":"J. Leukoc. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2026.118998_bib27","first-page":"5511","article-title":"Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis","volume":"162","author":"Keane","year":"1999","journal-title":"Journal immunology (Baltimore Md. 1950"},{"issue":"4","key":"10.1016\/j.biopha.2026.118998_bib28","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.3390\/ijms24043149","article-title":"Immune Mechanisms of Pulmonary Fibrosis with Bleomycin","volume":"24","author":"Ishida","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.118998_bib29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clinical experimental allergy journal British Society Allergy Clinical Immunology"},{"issue":"10","key":"10.1016\/j.biopha.2026.118998_bib30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","article-title":"Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial","volume":"4","author":"O'Byrne","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"174","key":"10.1016\/j.biopha.2026.118998_bib31","article-title":"Neutrophil dynamics in pulmonary fibrosis: pathophysiological and therapeutic perspectives","volume":"33","author":"Crowley","year":"2024","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","article-title":"Risk factors for diagnostic delay in idiopathic pulmonary fibrosis","volume":"20","author":"Hoyer","year":"2019","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.118998_bib33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC Trafficking with SX-682, a CXCR1\/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models","volume":"26","author":"Greene","year":"2020","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.118998_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2026.118998_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: A Review in Fibrotic Interstitial Lung Diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"1-3","key":"10.1016\/j.biopha.2026.118998_bib37","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12890-017-0405-7","article-title":"Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2\/Bach1 equilibrium","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.118998_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/ijms27010064","article-title":"In vivo target engagement assessment of nintedanib in a double-hit bleomycin lung fibrosis rat model","volume":"27","author":"Pitozzi","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.118998_bib40","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10753-023-01825-2","article-title":"Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K\/Akt\/mTOR Pathway in Mice","volume":"46","author":"Pan","year":"2023","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.biopha.2026.118998_bib41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2026.118998_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150020","article-title":"Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts","volume":"716","author":"Meng","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2011.01566.x","article-title":"Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1\/CXCR2 non-competitive allosteric inhibitor","volume":"165","author":"Bertini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.118998_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phrs.2015.11.005","article-title":"DF2755A, a novel non-competitive allosteric inhibitor of CXCR1\/2, reduces inflammatory and post-operative pain","volume":"103","author":"Lopes","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.119040","article-title":"A novel, orally active CXCR1\/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation","volume":"322","author":"Chapman","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.119040","article-title":"A novel, orally active CXCR1\/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation","volume":"322","author":"Rindgen","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.118998_bib47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-018-0236-x","article-title":"Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers","volume":"18","author":"Cullberg","year":"2018","journal-title":"Drugs RD"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:58:47Z","timestamp":1773979127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":47,"alternative-id":["S0753332226000302"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.118998","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.118998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118998"}}